Jun

11

 Two prominate drug companies decide to end thier HGH making deal, according to Forbes:

After partnering up only a year ago, investors and analysts were confused as to why Genentech chose to end its collaboration with Altus to jointly create HGH.

Altus (nasdaq: ALTU - news - people ) announced late Wednesday that it regained the rights from Genentech (nyse: DNA - news - people ) to develop and market the drug known as ALTU-238 in North America. According to Altus, Genentech declined an option to sell the drug internationally.

ALTU-238 is an experimental treatment intended for patients who lack the proper amount of the HGH. The drug, taken weekly, is a version of that hormone.

Why take chances with side effects associated with “real” HGH? Try a safe alternative with similiar benefits. Click here to find out more!

Dec

21

 Two prominate drug companies decide to end their HGH partnership, according to Forbes:

After partnering up only a year ago, investors and analysts were confused as to why Genentech chose to end its collaboration with Altus to jointly create HGH.

Altus announced late Wednesday that it regained the rights from Genentech to develop and market the drug known as ALTU-238 in North America. According to Altus, Genentech declined an option to sell the drug internationally.

ALTU-238 is an experimental treatment intended for patients who lack the proper amount of the HGH. The drug, taken weekly, is a version of that hormone.

 To read more about HGH, click here.

Forbes & HGH Drug Companies

Recommended Links

GET YOUR FREE HGH &
ANTI-AGING REPORT!